Evernow: Which Patient Profiles Should Avoid This Platform

What Evernow Is and How Its Care Model Works

Evernow is a direct-to-consumer menopause telehealth platform founded in 2020. It connects patients with licensed clinicians, primarily physicians and nurse practitioners, via asynchronous messaging and video visits. Patients pay a monthly subscription fee rather than billing insurance. Evernow prescribes FDA-approved hormone therapies including transdermal estradiol, oral progesterone (micronized progesterone, brand name Prometrium), and in some cases off-label testosterone for women.

The Asynchronous Care Model

Most communication on Evernow happens through text-based messaging rather than synchronous video calls. A patient fills out an intake questionnaire, a clinician reviews it, and a prescription may follow, sometimes without a live conversation. That workflow is efficient for straightforward cases, but it creates genuine information gaps for patients with nuanced medical histories.

The North American Menopause Society (NAMS) 2022 Position Statement states: "Individualization of care is essential, taking into account each woman's concerns, goals, and medical history." An asynchronous model can struggle to meet that standard when a patient has, for example, a first-degree relative with breast cancer combined with dense breasts and an elevated Tyrer-Cuzick score.

Prescribing Scope and Pharmacy Fulfillment

Evernow prescribes through both traditional pharmacies and compounding pharmacies. FDA-approved formulations carry established safety and efficacy data. Compounded hormones, by contrast, have not undergone FDA premarket review for safety or efficacy. The FDA has published explicit warnings that compounded hormone preparations are not FDA-approved and that claims of being "bioidentical" do not confer a safety advantage over approved products. [1]

Is Evernow Legit?

Yes, Evernow operates legally. It is incorporated in the United States, employs state-licensed clinicians, and prescribes within applicable telemedicine laws. Legitimacy, however, is not the same as clinical suitability for every patient.

Regulatory and Accreditation Standing

Evernow does not currently hold Better Business Bureau accreditation. A BBB rating reflects complaint-handling patterns and business transparency, not clinical quality, but its absence is a relevant data point for patients researching the platform. LegitScript, the pharmacy verification service used by Google and major payment processors, focuses on pharmacy-level compliance rather than telehealth platforms directly, so Evernow does not appear in LegitScript's database as a certified pharmacy.

State medical boards govern the clinicians Evernow employs. A clinician's license can be verified through the relevant state medical board website or through the Federation of State Medical Boards' DocInfo tool. Patients should confirm their assigned clinician holds an active, unrestricted license in their state of residence.

What Patient Complaints Reveal

Publicly available reviews on Google, Trustpilot, and Reddit forums (r/Menopause, r/Testosterone) show a recurring complaint pattern. Common themes include delayed clinician responses, difficulty adjusting dosing without a live conversation, and frustration when a clinician declines to prescribe a specific formulation the patient requested after reading about it online. A smaller number of complaints involve billing disputes and cancellation difficulties.

These complaints are important because they describe the real-world experience of the care model, not just its theoretical design. Delayed responses matter clinically when a patient is experiencing breakthrough bleeding or new symptoms that could signal something requiring urgent evaluation.

Absolute Contraindications to Hormone Therapy That Evernow Cannot Safely Manage

Certain medical conditions represent absolute contraindications to systemic hormone therapy regardless of the platform. Any telehealth service, including Evernow, should decline to prescribe HRT to patients in these categories. The clinical problem is that telehealth intake forms depend entirely on self-reported history, and patients may inadvertently omit or misunderstand their own diagnoses.

History of Hormone-Sensitive Cancers

Women with a personal history of estrogen-receptor-positive (ER+) breast cancer should not receive systemic estrogen therapy. The 2022 NAMS Position Statement and the American Cancer Society both recognize this as a firm contraindication. [2] The WHI Memory Study and the broader Women's Health Initiative (WHI) trial, which enrolled 16,608 participants, demonstrated increased breast cancer risk with combined estrogen-progestogen therapy after an average 5.6 years of follow-up (hazard ratio 1.26, 95% CI 1.00-1.59). [3]

Evernow's intake questionnaire asks about cancer history, but a text-based intake cannot replicate the clinical conversation that would identify, for example, a woman who had ductal carcinoma in situ (DCIS) treated with lumpectomy and radiation five years ago, then dismissed that history as "not really cancer."

Active or Recent Thromboembolic Disease

Active deep vein thrombosis, pulmonary embolism, or arterial thromboembolic events within the past 12 months are contraindications to oral estrogen. Transdermal estradiol carries a substantially lower thrombotic risk than oral formulations because it bypasses first-pass hepatic metabolism. The ESTHER study showed that transdermal estradiol was not associated with increased VTE risk (OR 0.9, 95% CI 0.5-1.6) compared with non-users, while oral estrogen carried an OR of 3.5 (95% CI 1.8-6.8). [4]

A woman with a Factor V Leiden mutation, antiphospholipid syndrome, or prior unprovoked DVT needs a hematology or vascular medicine consultation before any hormone therapy is prescribed. That consultation is outside Evernow's scope.

Undiagnosed or Unexplained Vaginal Bleeding

Postmenopausal bleeding is endometrial cancer until proven otherwise. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 128 specifies that women with postmenopausal bleeding require endometrial evaluation, typically with transvaginal ultrasound and, if the endometrial stripe exceeds 4 mm, endometrial biopsy. [5] Initiating progesterone or estrogen therapy before ruling out endometrial pathology would be clinically inappropriate. A telehealth intake form is not a substitute for that evaluation.

Active Liver Disease or Severely Impaired Liver Function

Estrogen metabolism depends heavily on hepatic function. Active hepatitis, cirrhosis, or liver tumors are contraindications to any systemic estrogen, including transdermal formulations. Evernow's intake process would need to rely on self-reported liver disease history and available lab values, which may not be current.

High-Risk Patient Profiles That Warrant In-Person Care Instead

Beyond absolute contraindications, several patient profiles carry elevated risk in a telehealth-only model, not because hormone therapy is necessarily off the table, but because the complexity demands closer monitoring and integrated care.

Cardiovascular Disease and Metabolic Syndrome

The WHI trial showed that combined HRT initiated in women over 60 or more than 10 years past menopause was associated with increased coronary heart disease risk (HR 1.29 in the estrogen-plus-progestin arm). [3] The "timing hypothesis," now supported by the Kronos Early Estrogen Prevention Study (KEEPS, N=727) and the Early versus Late Intervention Trial with Estradiol (ELITE, N=643), suggests that initiating estradiol within 6 years of menopause in women under 60 may actually reduce coronary atherosclerosis progression. [6]

Women with existing coronary artery disease, recent myocardial infarction, uncontrolled hypertension, or poorly controlled type 2 diabetes need individualized cardiovascular risk stratification before HRT is prescribed. That process requires a relationship with a cardiologist or an endocrinologist, not just a telehealth intake form.

BRCA1/BRCA2 Mutation Carriers

Women who carry a BRCA1 or BRCA2 mutation and have undergone risk-reducing bilateral salpingo-oophorectomy (BSO) occupy a nuanced clinical space. They face the cardiovascular, bone, and cognitive consequences of surgical menopause, often at a younger age, yet their baseline breast cancer risk is elevated. Hormone therapy decisions in this group should involve a genetic counselor and a high-risk breast oncologist. Evernow is not structured for that level of interdisciplinary coordination.

Premenopausal Women Seeking Off-Label Testosterone

Some premenopausal women seek testosterone through menopause-focused telehealth platforms for low libido or fatigue. Off-label testosterone prescribing in this population lacks the same evidence base as in postmenopausal women. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published simultaneously in multiple journals including the Journal of Clinical Endocrinology and Metabolism, endorsed testosterone only for hypoactive sexual desire disorder (HSDD) in postmenopausal women, at physiologic female-range doses. [7] Prescribing testosterone to premenopausal women outside that indication requires nuanced evaluation of ovarian function, androgen levels, and potential causes of low desire, work that a short intake form cannot accomplish.

Women on Tamoxifen or Aromatase Inhibitors

Patients currently taking tamoxifen (used for ER+ breast cancer treatment or prevention) or aromatase inhibitors (anastrozole, letrozole, exemestane) should not receive concurrent systemic estrogen. The pharmacologic purpose of those drugs is to reduce estrogen activity. Co-prescribing estrogen would directly counteract their mechanism. A clinician working from a telehealth intake form needs to recognize and flag this combination.

A Decision Framework: When to Choose Evernow vs. When to Seek In-Person Care

The decision is not binary between "Evernow" and "no care." It is a question of matching clinical complexity to care-model capabilities.

Evernow Is Likely Appropriate When

• The patient is a generally healthy woman aged 45-65 with vasomotor symptoms (hot flashes, night sweats) as her primary complaint.
• She has no personal history of cancer, thromboembolic events, or cardiovascular disease.
• She has a current primary care physician or gynecologist who handles her routine labs and annual screening (mammogram, Pap, lipid panel, metabolic panel).
• She understands the difference between FDA-approved hormone products and compounded formulations and can advocate for FDA-approved options.
• She is comfortable with asynchronous communication and can clearly describe symptom changes in writing.

Evernow Is Not Appropriate When

• She has any of the absolute contraindications listed above.
• She has had a breast cancer diagnosis of any receptor type within the past 10 years.
• She has an active or incompletely evaluated blood clotting disorder.
• She has new, unexplained, or postmenopausal vaginal bleeding that has not yet been evaluated.
• She is managing complex comorbidities, including insulin-dependent diabetes, autoimmune conditions on immunosuppressants, or severe psychiatric illness that interacts with hormone fluctuation.
• She cannot access same-day or next-day medical care in person if her condition acutely changes.

What the Evidence Says About Telehealth Menopause Care Quality

Telehealth for menopause management has genuine supporting evidence in appropriate populations. A 2021 systematic review published in Menopause (the journal of NAMS) found that telemedicine-delivered menopause care improved access to treatment and patient satisfaction scores compared with delayed or no care, particularly in rural populations. [8] Access matters. An estimated 10 million American women are in menopause transition at any given time, and access to menopause-trained clinicians remains uneven geographically.

The gap in evidence is at the high-complexity end. Studies supporting telehealth menopause care have generally enrolled patients who were already stable on therapy or had uncomplicated symptoms. They have not enrolled women with active cancer histories, coagulopathies, or cardiovascular disease.

Monitoring Requirements Telehealth Platforms Must Address

NAMS recommends that women on systemic HRT have annual follow-up visits to reassess the continued need for therapy, review any new symptoms, and confirm that age-appropriate cancer screening is current. [2] That annual review is clinically feasible via video telehealth. What is harder to ensure at scale is that labs ordered through the platform are actually completed, reviewed in context, and acted on promptly when values are abnormal.

Patients using Evernow should confirm in writing with their assigned clinician what the protocol is for reviewing lab results, what the expected response time is, and who covers if their primary clinician is unavailable.

Compounded Hormones Specifically: An Elevated-Risk Subsection

Evernow has at times directed patients toward compounding pharmacies for certain formulations. Compounded hormone therapy carries risks beyond those of FDA-approved products. The FDA's 2020 guidance document on compounded drug products notes that compounding pharmacies are not subject to the same manufacturing standards as drug manufacturers, creating batch-to-batch potency variability. [1]

The Endocrine Society's 2016 Scientific Statement on compounded bioidentical hormones concluded: "We found no evidence that custom-compounded bioidentical hormones are safer or more effective than government-approved menopausal hormone therapy." [9] That statement remains the position of the society.

Patients prescribed compounded hormones through Evernow should ask their clinician specifically why the FDA-approved equivalent is not being used for their case. A satisfactory answer requires a clinical reason, not a marketing preference.

Practical Steps Before Starting Evernow

Any woman considering Evernow should take these concrete steps before completing the intake.

Gather recent lab work, ideally from the prior 6 months, including FSH, estradiol, TSH, fasting lipid panel, fasting glucose or HbA1c, and a complete metabolic panel. Tell your Evernow clinician if any values were abnormal and what follow-up was recommended.

Confirm your mammogram is current. The U.S. Preventive Services Task Force (USPSTF) recommends biennial mammography beginning at age 40 for women at average risk. [10] Starting HRT without current breast imaging creates a baseline-documentation gap.

Identify an in-person clinician, whether a gynecologist, internist, or family medicine physician, who is aware you are using a telehealth hormone service. Evernow works best as a supplement to, not a replacement for, an established primary care relationship.

Ask Evernow explicitly whether the prescriptions they issue are for FDA-approved products or compounded formulations. Get the answer in writing through the platform's messaging system before your first prescription is filled.

A woman who follows these four steps before initiating care reduces her risk of falling through the gaps that telehealth intake forms create. Starting estradiol 0.05 mg/day transdermal patch plus micronized progesterone 200 mg/day for 12 days per month is a reasonable, guideline-supported regimen for an otherwise-healthy, recently menopausal 50-year-old woman with intact uterus. The same prescription in a 55-year-old woman with uninvestigated postmenopausal bleeding could mask or worsen an endometrial problem for months before it surfaces.